SoligenixSNGX
About: Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).
Employees: 15
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
1% more capital invested
Capital invested by funds: $260K [Q2] → $262K (+$2.7K) [Q3]
7.27% less ownership
Funds ownership: 10.17% [Q2] → 2.9% (-7.27%) [Q3]
36% less funds holding
Funds holding: 11 [Q2] → 7 (-4) [Q3]
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
67% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 6
Research analyst outlook
We haven’t received any recent analyst ratings for SNGX.
Financial journalist opinion
Based on 6 articles about SNGX published over the past 30 days
